Navigation Links
Intellect Neurosciences Enters Collaboration Agreement with Leading Alzheimer's Research Group at University of California Irvine to Test First in Class Dual Target Vaccine
Date:4/17/2012

NEW YORK, April 17, 2012 /PRNewswire/ -- Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment of Alzheimer's and other neurological diseases today announced it has entered into a collaboration agreement with the University California, Irvine to test RV03 a preclinical, first-in-class, dual acting peptide vaccine candidate to induce an immune response against beta amyloid and delta tau.  Delta tau is thought to be the earliest pathological form of tau protein prior to the formation of neurofibrillary tangles in the brain of Alzheimer's patients.  RV03 will be tested for both its therapeutic and prophylactic potential.  

(Logo: http://photos.prnewswire.com/prnh/20111214/NY22484LOGO )

Intellect will be collaborating with Dr. Frank LaFerla, Chancellor's Professor and Chair, Neurobiology and Behavior School of Biological Sciences, Director, Institute for Memory Impairments and Neurological Disorders and his team, in collaboration with Dr. Kim Green.   Previously, Dr. LaFerla's group proposed a novel mechanism establishing a causative link between the accumulation of beta amyloid in the brain of Alzheimer's patients and the formation of neurofibrillary tangles comprised of tau protein.  This was an important step towards explaining how these two different proteins act synergistically to cause irreversible damage and death of nerve cells. 

"These studies at the University of California at Irvine are an essential next step in the development of our RV03 program, and we anticipate positive results.  Once complete, we will be ready to embark on an aggressive development program to test RV03 in human clinical trials," said Dr. Daniel Chain, Chairman and CEO of Intellect Neurosciences.   "We look forward to working with
'/>"/>

SOURCE Intellect Neurosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Duff & Phelps Acquires Lumin Expert Group To Build Global Intellectual Property Practice
2. Codexis Names Vice President, Intellectual Property
3. Prometheus Strengthens Intellectual Property Portfolio with Newly Issued Patents for Thiopurine Metabolite Testing
4. CJPS Enterprises Provides New Strategies To Create Additional Revenues for Companies with Intellectual Property
5. Intellect Neurosciences, Inc. Issues Letter to Shareholders From Its Chairman and CEO
6. Epeius Biotech Awarded Patents in Europe for Targeted Genetic Anti-Cancer Medicine: Company Expands Impressive Intellectual Property Estate
7. Cancer Advances Acquires the Intellectual Property for a Suite of Products that Enhance the Immune System in Treatment of Gastric, Pancreatic, and Colorectal Cancers
8. Thomson Reuters Commemorates World IP Week with Series of Strategic Intellectual Property Seminars Across the U.S.
9. Hill-Rom Announces Sale of Negative Pressure Wound Therapy Intellectual Property
10. Epix Pharmaceuticals, Inc. Announces the PRX-08066 Therapeutics Program in Phase 2 for Respiratory Indication Will Be Part of The Intellectual Property Offered for Sale at the September 30, 2009 Auction
11. EPIX Pharmaceuticals, Inc. Announces the PRX-00023 Therapeutics CNS Program in Phase 2b/3 Will Be Part of the Intellectual Property Offered for Sale at the September 30, 2009 Auction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... 2015 /PRNewswire/ - RepliCel Life Sciences Inc. (TSX.V: ... company focused on the development of autologous cell ... the International Society for Cellular Therapy (ISCT) on ... currently in a Phase 1/2 clinical trial.  The ... from 5:30 PM to 7:00 PM local time, ...
(Date:5/20/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/x4b7kw/top_technologies ) has ... HW_Technical Insights" report to their offering. ... in the Health and Wellness sector and has identified ... impact in the year 2015. The research service provides ... and wellness technologies that are anticipated to have the ...
(Date:5/20/2015)... The global genotyping market is expected to ... period of 2015 to 2020 to reach $17.0billion in ... discovery and development process and to provide personalized therapy, ... this,heavy investments by key manufacturers to offer advanced and ... growth. Browse 113 market data tables & 37 figures ...
(Date:5/20/2015)... Mass. , May 20, 2015  Haemonetics Corporation ... Concannon , President & CEO, will present at The ... York on June 1 st , 2015 ... may access Mr. Concannon,s presentation live via webcast at: ... Haemonetics (NYSE: HAE ) is a global ...
Breaking Biology Technology:RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 2RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 3Top Technologies in the Health and Wellness Industry 2015 2Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 2Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 3Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 4Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 5
... MSEDMONTON, April 29 /PRNewswire-FirstCall/ - BioMS Medical Corp (TSX: MS), ... today announced that Mr. Kevin Giese, President and CEO, will ... development of a world class technology sector" as part of ... WHEN: Monday May 4th at ...
... April 29 In an effort to provide ... a New Jersey-based early-phase medical device company, has ... solution. The solution is designed to protect hospital ... life-threatening pathogens in healthcare facilities. It enables effective, ...
... - AEterna Zentaris Inc. (TSX: AEZ; Nasdaq: AEZS ... oncology, today announced it has received notification from the Nasdaq ... Rule 5450 (a) (1) relating to the maintenance of a ... was required to evidence a closing bid price of at ...
Cached Biology Technology:BioMS Medical to present at Alberta Economic Forum in Geneva 2Germgard's Ultra-Fast Hand Hygiene Solution Protects Against Deadly MRSA, C difficile, and Influenza Virus 2
(Date:5/11/2015)... Calif. , May 11, 2015  Synaptics ... of human interface solutions, today announced the appointment ... President and Chief Financial Officer, reporting to ... replaces Synaptics, current Chief Financial Officer, Kathleen ... 2014. Mr. Ali brings extensive ...
(Date:5/11/2015)... 2015 Curemark LLC, a privately held drug ... new Phase III double blind, randomized, placebo-controlled clinical trial ... on all children ages 3-8 with Autism. Previously, Curemark ... double blinded clinical trial for CM-AT in children ages ... digestive enzyme chymotrypsin. This new trial will help determine ...
(Date:5/8/2015)... 2015 Synaptics Inc. (NASDAQ: SYNA ), the ... of the executive management team will present at the following ... and Telecom Conference Date: May 18, 2015 Time: ... MA Cowen and Company Technology, Media ... Location: The New York Palace Hotel, New York, ...
Breaking Biology News(10 mins):Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2Synaptics to Present at Upcoming Investor Conferences 2
... clinical researchers will present findings about a one-two punch ... the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) ... is presenting data in two poster presentations that a ... percent of infectious airborne germs. Findings from these two ...
... Champaign, Ill., September 7, 2012 The University ... five new research teams joining the NASA Astrobiology Institute (NAI) ... five-year grant totaling approximately $8 million. Nigel Goldenfeld, ... theme at the Institute for Genomic Biology (IGB), will serve ...
... BUFFALO, N.Y. -- Tiny sea creatures called rhabdopleurids reside on ... of dead clams. Rhabdopleurid colonies are small, and the critters ... But they have lived this way -- and survived -- ... they have outlasted more elaborate species that also descended from ...
Cached Biology News:Research finds novel airborne germ-killing oral spray effective in fighting colds and flu 2University of Illinois at Urbana-Champaign awarded 5-year grant from NASA 2University of Illinois at Urbana-Champaign awarded 5-year grant from NASA 3Ancient, bottom-dwelling critter proves: Newer isn't always better 2
... has been designed and created in order ... friendly genotyping analysis tool. We incorporated the ... into the software. Their main requirements were ... low acquisition cost. GeneMarker can perform ...
... through columns is a well-known separation technique ... applications are in DNA/RNA extraction in microbiology, ... purification in chemical or analytical laboratories. ... Genesis series instruments for smaller scales. The ...
... structure visualization, phylogenetic tree building, sequence analysis, ... application. Retrieve sequences ... filter them in real-time Organize your ... filtering and sorting Provides up-to-date articles ...
Transfection Buffer A & B Set 5 ml each...
Biology Products: